What is COLL's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.77B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for COLL?

P/E (TTM) is 16.17 and 52-week range is $21.43 to $50.79 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s COLL figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for COLL?

The company profile lists revenue (TTM) near $811M, net income (TTM) near $48M, EPS (TTM) near $1.11 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Collegium Pharmaceutical, Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in Stoughton, Massachusetts, US, 32.6M shares outstanding, ISIN US19459J1043 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Collegium Pharmaceutical, Inc.

$COLL

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Collegium Pharmaceutical, Inc. is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. The company is headquartered in Stoughton, Massachusetts and currently employs 423 full-time employees. The company went IPO on 2015-05-07. The firm has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. Its portfolio also includes AZSTARYS (serdexmethylphenidate and dexmethylphenidate), a central nervous system (CNS) stimulant prescription medicine used for the treatment of ADHD in people six years of age and older.

Employees

423

Website

www.collegiumpharma.com/

IPO

2015-05-07

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US19459J1043

Headquarters

Stoughton, Massachusetts, US

Shares outstanding

32.6M

NAICS sector

Manufacturing

Institutional ownership

130.68%

Browse other companiesFree AI scores and summaries for more stocks